Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose

Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD), but it increases infection risk and impairs vaccine responses. Herein we evaluated the antibody response of RTX-treated patients to the supplemental COVID-19 vaccine. After the supplemental dose, 53.1% of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Emily, Magliulo, Daniel, Kyttaris, Vasileios C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547394/
https://www.ncbi.nlm.nih.gov/pubmed/36220613
http://dx.doi.org/10.1016/j.clim.2022.109144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547394/
https://www.ncbi.nlm.nih.gov/pubmed/36220613
http://dx.doi.org/10.1016/j.clim.2022.109144

Ejemplares similares